New Dehli, April 30, 2019 - SIFI, the Italian leader in the development of therapeutic solutions to treat ophthalmic disorders and global pharmaceutical major, Zydus Cadila, have tied up to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI.
SIFI's innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organization (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division). These surgical devices represent the most advanced solution for cataract refractive surgery and the correction of astigmatism (a type of refractive error where the cornea is irregularly shaped) and presbyopia (natural loss of the ability to focus on nearby objects that occurs with ageing).
‘Refractive cataract’ is nowadays at the frontier of cataract surgery as it combines clouded lens removal to the simultaneous correction of refractive errors such as myopia, hypermetropia, astigmatism and presbyopia, in order to free the patient from wearing glasses following the surgery.
The most advanced IOLs for this purpose are the EDOF (Extended Depth of Focus) lenses that present an optical plate with a continuous series of focuses to ensure a continuum correction from far to near in case of presbyopia and in case of astigmatism to provide compensation of the corneal abnormal curvature.
SIFI and Zydus look forward to bringing such innovations to India and to the entire South Asia region in order to empower surgeons with an advanced technology and consequently better the quality of vision and life of patients.
SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, nutraceuticals, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, France, Spain, Romania, Turkey and Mexico with a staff of more than 400 people worldwide. Since June 2015, SIFI is backed by the private equity 21 Invest to support the company’s international expansion and portfolio development strategy. More information available at www.sifigroup.com.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. For more information, please visit www.zyduscadila.com
email@example.com +393336999669 / Ada Puglisi 0039 095 7922145